Comparison of post-experimental outcome measures. by Neng Pan (5262032)

Subjects:

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

Subjects:

Individual stability values for different gait events under various conditions. by Hyung Suk Yang (20442438)

Subjects:

Dynamic stability based on the Feasible Stability Region (FSR). by Hyung Suk Yang (20442438)

Subjects:

Spatial dry and wet side fitting of the TS-NDVI characteristics for different time periods in the Santun River Irrigation Area: (a) 2006/05; (b) 2007/04; (c) 2008/10; (d) 2009/08;... by Yuxin Wei (11510974)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Additionally, the plots on the right side display the average plaque count across the cohorts. …”

Summary of codes generated from MAXQDA software. by Awole Seid (3839965)

Subjects:

Schematic presentation of themes and categories. by Awole Seid (3839965)

Subjects:

Background characteristics of study participants. by Awole Seid (3839965)

Subjects:

Conceptual model derived from interpretations of findings. by Awole Seid (3839965)

Subjects:

Summary of key questions and follow-up probes used in the phenomenological study. by Awole Seid (3839965)

Subjects:

Dataset. by Awole Seid (3839965)

Subjects:

S1 File - by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”